112 related articles for article (PubMed ID: 30342946)
1. Lipid modification of staphylokinase and its implications on stability and activity.
Mannully ST; Shanthi C; Pulicherla KK
Int J Biol Macromol; 2019 Jan; 121():1037-1045. PubMed ID: 30342946
[TBL] [Abstract][Full Text] [Related]
2. Purification and in vivo stability and half-life of recombinant lipid modified staphylokinase.
Mannully ST; Rekha VPB; Singh N; Shanthi C; Pulicherla KK
Biologicals; 2020 Mar; 64():15-22. PubMed ID: 32035733
[TBL] [Abstract][Full Text] [Related]
3. Integration of VEK-30 peptide enhances fibrinolytic properties of staphylokinase.
Bhando T; Singh S; Hade MD; Kaur J; Dikshit KL
Biotechnol Appl Biochem; 2021 Apr; 68(2):213-220. PubMed ID: 32233032
[TBL] [Abstract][Full Text] [Related]
4. Effect of site-specific PEGylation on the fibrinolytic activity, immunogenicity, and pharmacokinetics of staphylokinase.
Liu J; Wang Z; He J; Wang G; Zhang R; Zhao B
Acta Biochim Biophys Sin (Shanghai); 2014 Sep; 46(9):782-91. PubMed ID: 25098624
[TBL] [Abstract][Full Text] [Related]
5. Kinetic studies on the plasminogen activation by the staphylokinase-plasmin complex.
Shibata H; Nagaoka M; Sakai M; Sawada H; Watanabe T; Yokokura T
J Biochem; 1994 Apr; 115(4):738-42. PubMed ID: 8089091
[TBL] [Abstract][Full Text] [Related]
6. A new recombinant thrombolytic and antithrombotic agent with higher fibrin affinity--a staphylokinase variant. I. In vitro study.
Szemraj J; Walkowiak B; Kawecka I; Janiszewska G; Buczko W; Bartkowiak J; Chabielska E
J Thromb Haemost; 2005 Oct; 3(10):2156-65. PubMed ID: 16150047
[TBL] [Abstract][Full Text] [Related]
7. Characterization of a novel bifunctional mutant of staphylokinase with platelet-targeted thrombolysis and antiplatelet aggregation activities.
Chen H; Mo W; Su H; Zhang Y; Song H
BMC Mol Biol; 2007 Oct; 8():88. PubMed ID: 17919340
[TBL] [Abstract][Full Text] [Related]
8. A correlation between thermal stability and structural features of staphylokinase and selected mutants: a Fourier-transform infrared study.
Dornberger U; Fandrei D; Backmann J; Hübner W; Rahmelow K; Gührs KH; Hartmann M; Schlott B; Fritzsche H
Biochim Biophys Acta; 1996 May; 1294(2):168-76. PubMed ID: 8645735
[TBL] [Abstract][Full Text] [Related]
9. Staphylokinase as a plasminogen activator component in recombinant fusion proteins.
Szarka SJ; Sihota EG; Habibi HR; Wong S
Appl Environ Microbiol; 1999 Feb; 65(2):506-13. PubMed ID: 9925575
[TBL] [Abstract][Full Text] [Related]
10. Cloning and expression of a new recombinant thrombolytic and anthithrombotic agent - a staphylokinase variant.
Kowalski M; Brown G; Bieniasz M; Oszajca K; Chabielska E; Pietras T; Szemraj Z; Makandjou-Ola E; Bartkowiak J; Szemraj J
Acta Biochim Pol; 2009; 56(1):41-53. PubMed ID: 19018330
[TBL] [Abstract][Full Text] [Related]
11. Kinetic analysis of plasminogen activation by staphylokinase/plasminogen complex in the presence of fibrin.
Okada K; Yuasa H; Hagiya Y; Fukao H; Ueshima S; Matsuo O
Thromb Res; 1994 Oct; 76(2):181-91. PubMed ID: 7863467
[TBL] [Abstract][Full Text] [Related]
12. Designing a multifunctional staphylokinase variant (SAK-2RGD-TTI) with appropriate thrombolytic activity in vitro.
Faraji H; Soltani F; Ramezani M; Sadeghnia HR; Nedaeinia R; Moghimi Benhangi H; Mashkani B
Biotechnol Lett; 2020 Jan; 42(1):103-114. PubMed ID: 31686286
[TBL] [Abstract][Full Text] [Related]
13. Involvement of protease inhibitors in staphylokinase-induced fibrin-specific fibrinolysis.
Shishido Y; Sakai M; Kaneda N; Sansawa H; Shimura K; Hashimoto S; Yokokura T
Biol Pharm Bull; 1994 Dec; 17(12):1595-8. PubMed ID: 7735201
[TBL] [Abstract][Full Text] [Related]
14. Novel recombinant thrombolytic and antithrombotic staphylokinase variants with an RGD motif at their N-termini.
He J; Di J; Xu R; Zhao B
Biotechnol Appl Biochem; 2008 May; 50(Pt 1):17-23. PubMed ID: 18039183
[TBL] [Abstract][Full Text] [Related]
15. Novel self-cleavage activity of Staphylokinase fusion proteins: An interesting finding and its possible applications.
Prasad B; Salunkhe SS; Padmanabhan S
Protein Expr Purif; 2010 Feb; 69(2):191-7. PubMed ID: 19638310
[TBL] [Abstract][Full Text] [Related]
16. [Expression, purification and characterization of a novel staphylokinase with anti-platelet aggregation activity].
Jingfang D; Jintian H; Ruiguang X; Xi C; Baohua Z
Wei Sheng Wu Xue Bao; 2008 Sep; 48(9):1186-91. PubMed ID: 19062642
[TBL] [Abstract][Full Text] [Related]
17. Staphylokinase-annexin XI chimera exhibited efficient in vitro thrombolytic activities.
Chiou JF; Woon MD; Cheng SN; Hsu CH; Cherng SC; Hsieh FK; Lin SM; Shiau CY
Biosci Biotechnol Biochem; 2007 May; 71(5):1122-9. PubMed ID: 17485856
[TBL] [Abstract][Full Text] [Related]
18. Refolding of a staphylokinase variant y1-Sak by reverse dilution.
He J; Wang G; Xu R; Feng J; Wang J; Su H; Song H
Appl Biochem Biotechnol; 2008 Oct; 151(1):29-41. PubMed ID: 18785020
[TBL] [Abstract][Full Text] [Related]
19. Functional properties of recombinant staphylokinase variants obtained by site-specific mutagenesis of methionine-26.
Schlott B; Hartmann M; Gührs KH; Birch-Hirschfeld E; Gase A; Vettermann S; Collen D; Lijnen HR
Biochim Biophys Acta; 1994 Feb; 1204(2):235-42. PubMed ID: 8142464
[TBL] [Abstract][Full Text] [Related]
20. In vitro characterization of a multifunctional staphylokinase variant with reduced reocclusion, produced from salt inducible E. coli GJ1158.
Pulicherla KK; Kumar A; Gadupudi GS; Kotra SR; Rao KR
Biomed Res Int; 2013; 2013():297305. PubMed ID: 23998121
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
